Cantor Fitzgerald assumed coverage on shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) in a research report sent to investors on Tuesday. The brokerage issued a buy rating and a $17.00 target price on the biopharmaceutical company’s stock.
Separately, Aegis restated a buy rating on shares of Corbus Pharmaceuticals Holdings in a research note on Sunday, August 21st.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded up 18.38% during midday trading on Tuesday, reaching $8.31. The company had a trading volume of 2,440,627 shares. The company’s 50 day moving average is $5.38 and its 200-day moving average is $3.34. The company’s market capitalization is $363.55 million. Corbus Pharmaceuticals Holdings has a 52-week low of $1.01 and a 52-week high of $8.40.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last issued its earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.03. Corbus Pharmaceuticals Holdings had a negative return on equity of 107.10% and a negative net margin of 890.44%. Equities analysts expect that Corbus Pharmaceuticals Holdings will post ($0.40) earnings per share for the current fiscal year.
In other news, insider Barbara White purchased 38,000 shares of the company’s stock in a transaction on Wednesday, August 17th. The shares were bought at an average price of $3.15 per share, for a total transaction of $119,700.00. Following the completion of the purchase, the insider now owns 161,067 shares of the company’s stock, valued at $507,361.05. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Sean F. Moran purchased 148,960 shares of the company’s stock in a transaction on Thursday, August 18th. The stock was purchased at an average price of $3.32 per share, for a total transaction of $494,547.20. Following the purchase, the chief financial officer now directly owns 216,410 shares of the company’s stock, valued at approximately $718,481.20. The disclosure for this purchase can be found here. 11.60% of the stock is currently owned by company insiders.
About Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.
Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.